PATENTSCOPE: EN_ALL:nmr AND PA:abbott

METHODS FOR AIDING IN DIAGNOSING AND EVALUATING A MILD TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING CARDIAC TROPONIN I (Fri, 07 Dec 2018)
Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate, severe, or moderate to severe traumatic brain injury (TBI), using cTnI. Also disclosed are methods for determining whether to perform a head computerized tomography on a subject by detecting levels of cTnI. Finally, also disclosed are methods of outcome in subjects suffering from a mild TBI.
>> Read More

METHODS FOR AIDING IN DIAGNOSING AND EVALUATING A MILD TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING CARDIAC TROPONIN I AND EARLY BIOMARKERS (Fri, 07 Dec 2018)
Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or a moderate, severe, or moderate to severe traumatic brain injury (TBI), by detecting levels of cardiac troponin I (cTnI) and one or more early biomarkers which are not cTnI, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in biological samples taken from a human subject at time points within about 24 hours of injury after the subject has sustained or may have sustained the injury to the head.
>> Read More

METHODS FOR AIDING IN THE DETERMINATION OF WHETHER TO PERFORM IMAGING ON A HUMAN SUBJECT WHO HAS SUSTAINED OR MAY HAVE SUSTAINED AN INJURY TO THE HEAD USING EARLY BIOMARKERS (Fri, 30 Nov 2018)
Disclosed herein are methods that aid in the determination of whether to perform imaging, such as magnetic resonance imaging (MRI) or computerized tomography (CT) scan, on a human subject that has sustained or may have sustained an injury to the head using an early biomarker, such as ubiquitin carboxy-terminal hydrolase LI (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. These methods involve detecting levels and changes in levels of UCH-L1 and/or GFAP in samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.
>> Read More

ACCELERATED AGING FOR POLYMERIC SCAFFOLDS (Fri, 16 Nov 2018)
A method of accelerated aging of bioresorbable polymer scaffolds (10) including exposing the scaffold to water is disclosed. The scaffold (10) is exposed to water at a controlled temperature for a selected aging time. The functional outputs, such as radial strength, expandability, and %recoil obtained from aged scaffolds predict those of real-time aging of the scaffold. The accelerated aging factor, which is the required shelf life divided by the aging time, is significantly higher for poly(L-lactide) scaffolds tested than thermal aging.
>> Read More

METHODS FOR AIDING IN THE HYPERACUTE DIAGNOSIS AND DETERMINATION OF TRAUMATIC BRAIN INJURY USING EARLY BIOMARKERS ON AT LEAST TWO SAMPLES FROM THE SAME HUMAN SUBJECT (Fri, 02 Nov 2018)
Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild, moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperacute determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting changes of levels of an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a human subject at a time point within about 2 hours, such as about 10, 12, or 20 minutes, after the subject has sustained or may have sustained an injury to the head and a second time point about 3 hours to about 6 hours after the first sample is taken.
>> Read More

METHODS FOR AIDING IN THE HYPERACUTE DIAGNOSIS AND DETERMINATION OF TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING EARLY BIOMARKERS (Fri, 19 Oct 2018)
Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperacute determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting levels of early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a human subject at a time point within about 2 hours, such as about 10, 12, or 20 minutes, after the subject has sustained or may have sustained an injury to the head.
>> Read More

METHODS FOR AIDING IN THE DIAGNOSIS AND DETERMINATION OF THE EXTENT OF TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING THE EARLY BIOMARKER UBIQUITIN CARBOXY-TERMINAL HYDROLASE L1 (Fri, 28 Sep 2018)
Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate to severe traumatic brain injury (TBI), using an early biomarker, ubiquitin carboxy-terminal hydrolase L1 (UCH-L1). Also disclosed here are methods that aid in determining whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting levels and changes in levels of UCH-L1 in one or more samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.
>> Read More

IMPROVED METHODS OF ASSESSING UCH-L1 STATUS IN PATIENT SAMPLES (Fri, 13 Apr 2018)
Disclosed herein are improved methods of assessing ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) status in a subject (such as for example, as a measure of traumatic brain injury or for other clinical reasons). Also disclosed herein are methods of assessing a subject's glial fibrillary acid protein (GFAP) and UCH-L1 status in subject (such as, for example as a measure of traumatic brain injury or for other clinical reasons).
>> Read More

IMPROVED METHODS OF ASSESSING GFAP STATUS IN PATIENT SAMPLES (Fri, 13 Apr 2018)
Disclosed herein are improved methods of assessing Glial fibrillary acidic protein (GFAP) status in a subject (such as for examples, as a measure of traumatic brain injury or for other clinical reasons).
>> Read More

BIOMARKERS TO PREDICT NEW ONSET HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) (Fri, 22 Dec 2017)
The invention provides methods of detecting a natriuretic protein, a troponin, and galectin-3 in samples from subjects in order to determine risk of developing new onset heart failure with preserved ejection fraction (HFpEF).
>> Read More

DRUG-ELUTING COATINGS ON POLY(DL-LACTIDE)-BASED SCAFFOLDS (Fri, 06 Jan 2017)
Stents including a poly(D,L-lactide)(PDLLA)-based scaffold and PDLLA based therapeutic layer are disclosed. The PDLLA based scaffold may be amorphous and may include a primer layer. Methods of applying the PDLLA-based coating to the scaffold are disclosed with solvent processing methods using a solvent blend are also disclosed. Methods of removing residual solvent from a PDLLA-base coating that also condition the scaffold are disclosed. Methods of treating restenosis that release drugs to prevent restenosis without interfering with the natural positive remodeling of a vessel are disclosed.
>> Read More

PROCESS OF MAKING SCAFFOLD WITH INTERFACE TO PROMOTE COATING ADHESION (Fri, 30 Dec 2016)
Methods of fabricating a stent are disclosed including forming a primer layer on a surface of the scaffold including a first polylactide polymer. The primer layer includes a second polylactide polymer and is free of a therapeutic agent. The scaffold with the primer layer is thermally treated to condition the scaffold. A therapeutic layer is formed over the primer layer and the therapeutic layer includes the second polylactide polymer and a drug. The scaffold is crimped and the primer layer improves adhesion of the therapeutic layer to the scaffold and reduces or prevents damage to the therapeutic layer during crimping.
>> Read More

THERMAL PROCESSING OF POLYMER SCAFFOLDS (Fri, 25 Mar 2016)
Method is disclosed including thermally processing a scaffold to increase the radial strength of the scaffold when the scaffold is deployed from a crimped state to a deployed state such as a nominal deployment diameter. The thermal processing may further maintain or increase the expansion capability of the scaffold when expanded beyond the nominal diameter.
>> Read More

METHODS FOR SOLID PHASE PROCESSING OF TUBES AND MEDICAL DEVICES MADE FROM THE PROCESSED TUBES (Fri, 05 Feb 2016)
A polymer tube is processed using a solid phase process for improving mechanical characteristics of the tube, including radial strength and stiffness. The tube is made into a scaffold possessing improved mechanical and use characteristics, such as a reduced crimped profile and improved deliverability.
>> Read More

NUTRITIONAL POWDER WITH SPECIFIC ANTIOXIDANTS (Fri, 29 Jan 2016)
Disclosed herein are nutrient delivery systems that provide a nutritional formula for consumption. The nutrient delivery system includes a pod and a nutritional powder comprising at least one antioxidant. The nutritional powder has improved oxidative qualities such as increased shelf life.
>> Read More

NUTRITIONAL POWDER WITH POLYUNSATURATED FATTY ACID AND IMPROVED ORGANOLEPTIC PROPERTIES (Fri, 29 Jan 2016)
Disclosed herein is a nutrient delivery system comprising a pod. The pod comprises a nutritional powder that comprises a polyunsaturated fatty acid and at least one antioxidant. The nutrient delivery system delivers a nutritional formula to a container to supply nourishment to an infant.
>> Read More

POLYLACTIDE AND POLYCAPROLACTONE COPOLYMER AND BLENDS FOR BIORESORBABLE VASCULAR SCAFFOLDS (Thu, 24 Dec 2015)
Bioresorbable polymer vascular scaffolds made of combinations of polylactide and polycaprolactone having thin struts in a selected range and sufficient radial strength to support a vessel upon deployment are disclosed. The scaffolds have degradation behavior of molecular weight, radial strength, and mass that are conducive to healing of a vessel including providing patency to a vessel, reduction of radial strength, breaking up, and resorbing to allow return of the vessel to a natural state.
>> Read More

DRUG DELIVERY SCAFFOLD OR STENT WITH A NOVOLIMUS AND LACTIDE BASED COATING SUCH THAT NOVOLIMUS HAS A MINIMUM AMOUNT OF BONDING TO THE COATING (Fri, 14 Aug 2015)
Disclosed herein are drug delivery medical devices. A polymer coating for a medical device is provided which comprises a minimum amount of a drug bonded to the polymer in the coating.
>> Read More

MODIFIED PLA POLYMER AND METHOD OF MAKING AND USING (Fri, 14 Aug 2015)
It is provided herein modified polylactide (PLA) polymers comprising biocompatibile functional group(s) on the polymers and methods of making and using the modified PLA polymers.
>> Read More

NUCLEOTIDE ANALOGS (Fri, 27 Feb 2015)
Provided herein is technology relating to the manipulation and detection of nucleic acids, including but not limited to compositions, methods, and kits related to nucleotides comprising a chemically reactive linking moiety.
>> Read More